A Phase II Evaluation of Nintedanib (BIBF-1120) in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

INTRODUCTION: Patients presenting with advanced, recurrent, or metastatic endometrial cancer have limited treatment options. On behalf of the Gynecologic Oncology Group, we conducted this phase II trial of nintedanib (BIBF 1120), a potent small molecule triple receptor tyrosine kinase inhibitor of P...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Gynecol Oncol
Autori principali: Dizon, Don S., Sill, Michael W., Schilder, Jeanne M., McGonigle, Kathryn F., Rahman, Zia, Miller, David S., Mutch, David G., Leslie, Kimberly K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2014
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4373614/
https://ncbi.nlm.nih.gov/pubmed/25312396
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2014.10.001
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi